4/5
05:39 pm
ewtx
Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money [Yahoo! Finance]
Medium
Report
Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money [Yahoo! Finance]
4/3
11:34 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target lowered by analysts at Royal Bank of Canada from $56.00 to $52.00. They now have an "outperform" rating on the stock.
Medium
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target lowered by analysts at Royal Bank of Canada from $56.00 to $52.00. They now have an "outperform" rating on the stock.
4/2
06:21 pm
ewtx
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged [Yahoo! Finance]
Medium
Report
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged [Yahoo! Finance]
4/2
02:15 pm
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $51.00 price target on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $51.00 price target on the stock.
4/2
12:18 pm
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) was downgraded by analysts at Scotiabank from a "sector outperform" rating to a "sector perform" rating. They now have a $14.00 price target on the stock.
Medium
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) was downgraded by analysts at Scotiabank from a "sector outperform" rating to a "sector perform" rating. They now have a $14.00 price target on the stock.
4/2
12:18 pm
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) was downgraded by analysts at Scotiabank from a "sector outperform" rating to a "sector perform" rating. They now have a $14.00 price target on the stock.
Medium
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) was downgraded by analysts at Scotiabank from a "sector outperform" rating to a "sector perform" rating. They now have a $14.00 price target on the stock.
4/2
06:22 am
ewtx
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
High
Report
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
4/2
06:16 am
ewtx
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) [Yahoo! Finance]
High
Report
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) [Yahoo! Finance]
4/2
06:00 am
ewtx
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
High
Report
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
3/26
04:45 pm
ewtx
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
Medium
Report
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
3/11
08:39 am
ewtx
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference [Yahoo! Finance]
Low
Report
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference [Yahoo! Finance]
3/11
08:00 am
ewtx
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
Low
Report
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
3/7
08:17 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $50.00 price target on the stock.
Neutral
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $50.00 price target on the stock.
3/4
10:25 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $56.00 price target on the stock.
Low
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $56.00 price target on the stock.
3/4
08:00 am
ewtx
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
Low
Report
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
3/3
08:11 am
ewtx
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/3
08:00 am
ewtx
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Low
Report
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
2/19
10:58 am
ewtx
Should You Invest in Edgewise Therapeutics (EWTX)? [Yahoo! Finance]
Low
Report
Should You Invest in Edgewise Therapeutics (EWTX)? [Yahoo! Finance]
1/22
09:05 am
ewtx
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development [Yahoo! Finance]
1/22
08:12 am
ewtx
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating and a $30.00 price target on the stock.
Medium
Report
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating and a $30.00 price target on the stock.
1/22
08:00 am
ewtx
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
Medium
Report
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development